Avalo Therapeutics, INC. (AVTX) — 8-K Filings

All 8-K filings from Avalo Therapeutics, INC.. Browse 26 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (26)

Avalo Therapeutics Files 8-K — Dec 2, 2025 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on December 2, 2025, reporting an "Other Events" item. The company, formerly known as Cerecor Inc. until November 2, 2011,
Avalo Therapeutics Files 8-K — Oct 29, 2025 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting other events and financial statements. The company, formerly known as Cerecor Inc. until No
Avalo Therapeutics Files 8-K — Oct 10, 2025 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on October 10, 2025, reporting other events and financial statements. The company, formerly known as Cerecor Inc. until No
Avalo Therapeutics Reports Director/Officer Changes & More — Oct 1, 2025 Risk: medium
Avalo Therapeutics, Inc. filed an 8-K on October 1, 2025, reporting on events as of September 29, 2025. The filing covers the departure of directors or certain
Avalo Therapeutics Files 8-K on Officer/Director Changes — Sep 22, 2025 Risk: medium
Avalo Therapeutics, Inc. filed an 8-K on September 22, 2025, reporting events as of September 16, 2025. The filing covers the departure of directors or certain
Avalo Therapeutics Files 8-K — Jun 20, 2025 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on June 20, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific d
Avalo Therapeutics Announces Board Changes and Executive Compensation Updates — Jun 18, 2025 Risk: medium
Avalo Therapeutics, Inc. announced on June 17, 2025, a series of significant corporate actions. These include the departure of certain directors and officers, t
Avalo Therapeutics Files 8-K on Security Holder Vote — Jun 17, 2025 Risk: medium
On June 17, 2025, Avalo Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders. N
Avalo Therapeutics Announces Material Agreements — Jun 5, 2025 Risk: medium
On June 3, 2025, Avalo Therapeutics, Inc. entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The filing details t
Avalo Therapeutics Files 8-K — Jun 4, 2025 Risk: low
On June 4, 2025, Avalo Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information related to "Other Events" and "Fin
Avalo Therapeutics Files 8-K — May 8, 2025 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on May 8, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Cerecor I
Avalo Therapeutics Files 8-K on Director/Officer Changes — Mar 26, 2025 Risk: low
On March 25, 2025, Avalo Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing
Avalo Therapeutics Files 8-K — Jan 13, 2025 Risk: low
On January 13, 2025, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material ev
Avalo Therapeutics Files 8-K on Officer/Director Changes — Jan 2, 2025 Risk: medium
On January 1, 2025, Avalo Therapeutics, Inc. (formerly Cerecor Inc.) filed an 8-K report. The filing indicates changes related to the departure of directors or
Avalo Therapeutics Files 8-K — Dec 5, 2024 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on December 5, 2024, reporting other events and financial statements. The company, formerly known as Cerecor Inc., is inco
Avalo Therapeutics Files 8-K — Nov 12, 2024 Risk: low
Avalo Therapeutics, Inc. filed an 8-K on November 12, 2024, reporting other events and financial statements. The company, formerly known as Cerecor Inc., is inc
Avalo Therapeutics Files 8-K — Oct 8, 2024 Risk: low
On October 8, 2024, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicati
Avalo Therapeutics Files 8-K Report — Sep 9, 2024 Risk: low
On September 9, 2024, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
Avalo Therapeutics Appoints New Chief Medical Officer — Sep 4, 2024 Risk: medium
On September 3, 2024, Avalo Therapeutics, Inc. (AVTX) announced the appointment of Dr. David E.I. Cromwell as Chief Medical Officer. Dr. Cromwell brings extensi
Avalo Therapeutics to be Acquired by Ares Acquisition Corp. — Aug 14, 2024 Risk: medium
Avalo Therapeutics, Inc. (AVTX) announced on August 13, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Ares Acquisition
Avalo Therapeutics Merges with LumiraDx, Renamed LumiraDx — Jul 30, 2024 Risk: medium
On July 29, 2024, Avalo Therapeutics, Inc. announced the closing of its previously disclosed merger with LumiraDx Limited. The merger was approved by Avalo's st
Avalo Therapeutics Board Changes — Jul 16, 2024 Risk: medium
Avalo Therapeutics, Inc. announced on July 15, 2024, a change in its board of directors. Specifically, Dr. Jonathan M. Rothberg has resigned from his position a
Avalo Therapeutics Files 8-K for Financials and Exhibits — Jul 9, 2024 Risk: low
On July 9, 2024, Avalo Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, with no other spec
Avalo Therapeutics Faces Nasdaq Delisting — May 23, 2024 Risk: high
Avalo Therapeutics, Inc. (AVTX) received a notice on May 20, 2024, indicating it failed to meet the continued listing standards of the Nasdaq Capital Market. Th
Avalo Therapeutics Reports Material Agreement, Delisting Notice — Mar 28, 2024 Risk: high
Avalo Therapeutics, Inc. announced on March 27, 2024, that it entered into a Material Definitive Agreement. The company also provided updates on the completion
Avalo Therapeutics Files 8-K for 'Other Event' on Jan 30 — Jan 31, 2024
Avalo Therapeutics, Inc. filed an 8-K on January 31, 2024, reporting an "Other Event" that occurred on January 30, 2024. This filing is a routine administrative

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX